MUNSTER – Community Hospital in Munster is one o 200 hospitals nationwide that will participate in a National Cancer Institute-sponsored study to evaluate the cholesterol drug Rosuvastatin (Crestor) as a treatment to reduce the risk of colon cancer.

            Rosuvastatis is in a class of drugs that lower cholesterol. The study was developed because laboratory research and studies conducted in large populations of patients taking a statin to reduce cholesterol suggest that taking the drug may also decrease the number of colon polyps.

            “We are pleased to be able to offer Northwest Indiana residents access to the new National Cancer Institute study that may change the way we treat colon cancer in the future,” said Erwin Robin, medical director of cancer research at Community Hospital.